Zenocutuzumab Showcases Robust, Durable Efficacy in Advanced NRG1+ Cancer, Irrespective of Tumor Histology
June 5th 2022
Zenocutuzumab was found to produce durable responses in patients with previously treated advanced NRG1-positive cancers, with antitumor activity observed across several tumor types, and to have an extremely well tolerated toxicity profile, according to data from a phase 1/2 trial (NCT02912949).